VYNE Therapeutics (VYNE) EBT Margin Growth (3y) (2020 - 2026)

VYNE Therapeutics (VYNE) EBT Margin Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9,237.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -408.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 363.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 VYNE Therapeutics 1.19 Bn 1.16 Bn - 144,340.00

Historic Data

Download Data
DateValue
Mar 31, 2026 144,340.00
Jun 30, 2025 78,871.00
Mar 31, 2025 58,277.00
Dec 31, 2024 -1.12 Mn
Sep 30, 2024 68,673.00
Jun 30, 2024 -112,292.00
Mar 31, 2024 -151,230.00
Dec 31, 2023 -755,388.00
Sep 30, 2023 -456,946.00
Jun 30, 2023 -860,320.00
Mar 31, 2023 -331,297.00
Dec 31, 2022 129,757.00
Mar 31, 2022 10,924.00
Dec 31, 2021 -381,701.00
Jun 30, 2021 -343,217.00
Mar 31, 2021 1.51 Mn
Dec 31, 2020 66,801.00
Sep 30, 2020 16,305.00
Jun 30, 2020 -5,016.00
Mar 31, 2020 -106,094.00